Deutsch English Français

Contact

EP2475389

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2475389

EP2475389 - USE OF AN ANTI-IL6 ANTIBODY TO DECREASE HEPCIDIN IN CANCER PATIENTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 28.02.2014 Database last updated on 20.07.2024
Most recent event Tooltip	28.02.2014	Application deemed to be withdrawn	published on 02.04.2014 [2014/14]
Applicant(s)	For all designated states Janssen Biotech, Inc. 800/850 Ridgeview Drive Horsham, PA 19044 / US
	[2012/29]
Inventor(s)	01 / CORNFELD, Mark 920 Route 202 Raritan, NJ 08869 / US
	02 / REDDY, Manjula 145 King of Prussia Road Rodnor, PA 19087 / US
	03 / QIN, Xiang 965 Chesterbrook Blvd. Wayne, PA 19087 / US
	04 / RIJNBEEK, Britte Einsteinweg 92 Postbus 251 NL-2300 AG Leiden / NL
	[2012/29]
Representative(s)	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2012/29]	Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB
Application number, filing date	10815958.3	07.09.2010
	WO2010US47943
Priority number, date	US20090240363P	08.09.2009 Original published format: US 240363 P
	[2012/29]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011031657
	Date:	17.03.2011
	Language:	EN
	[2011/11]
	Type:	A1 Application with search report
	No.:	EP2475389
	Date:	18.07.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.03.2011 takes the place of the publication of the European patent application.
	[2012/29]
Search report(s)	International search report - published on:	US	17.03.2011
	(Supplementary) European search report - dispatched on:	EP	07.03.2013
Classification	IPC:	A61K39/395	[2012/29]
	CPC:	C07K16/248 (EP,US); A61P19/02 (EP); A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP); A61P35/00 (EP); (+) A61P35/02 (EP); A61P43/00 (EP); A61P7/06 (EP); A61K2039/505 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/29]
Extension states	BA	04.04.2012
Title	German:	VERWENDUNG EINES ANTIKÖRPERS GEGEN IL6 FÜR HEPCIDINABBAU BEI KREBSPATIENTEN	[2012/29]
	English:	USE OF AN ANTI-IL6 ANTIBODY TO DECREASE HEPCIDIN IN CANCER PATIENTS	[2012/29]
	French:	UTILISATION D'UN ANTICORPS ANTI-IL6 POUR RÉDUIRE L'HEPTICIDINE CHEZ DES PATIENTS ATTEINTS DE CANCER	[2012/29]
Entry into regional phase	04.04.2012	National basic fee paid
	04.04.2012	Search fee paid
	04.04.2012	Designation fee(s) paid
	04.04.2012	Examination fee paid
Examination procedure	04.04.2012	Amendment by applicant (claims and/or description)
	04.04.2012	Examination requested [2012/29]
	08.10.2013	Application deemed to be withdrawn, date of legal effect [2014/14]
	13.11.2013	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2014/14]
Fees paid	Renewal fee
	12.09.2012	Renewal fee patent year 03
	12.09.2013	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XD] - VAN RHEE FRITS ET AL, "CNTO 328, a Monoclonal Antibody to Interleukin-6. Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study.", BLOOD, & 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008, (200811), vol. 112, no. 11, ISSN 0006-4971, page 371, XP002692399 [XD] 1-15 * abstract *
		[X] - KURZROCK RAZELLE ET AL, "A Phase I Study of CNTO 328, An Anti-Interelukin-6 Monoclonal Antibody in Patients with A-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.", BLOOD, & 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008, (200811), vol. 112, no. 11, ISSN 0006-4971, pages 371 - 372, XP002692400 [X] 1-15 * abstract *
		[ID] - BECK J T ET AL, "BRIEF REPORT: ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMAN'S DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, (19940303), vol. 330, no. 9, doi:10.1056/NEJM199403033300904, ISSN 0028-4793, pages 602 - 605, XP002937044 [ID] 1-15 * the whole document * DOI: http://dx.doi.org/10.1056/NEJM199403033300904
		[A] - "Murine anti-IL-6 CLB-8 antibody variable region light chain.", Geneseq, (20040729), Database accession no. ADO16879, URL: EBI, XP002692401 [A] 1-15 * abstract *
		[A] - "Murine anti-IL-6 CLB-8 antibody variable region heavy chain.", Geneseq, (20040729), Database accession no. ADO16878, URL: EBI, XP002692402 [A] 1-15 * abstract *
	International search	[Y]US2008312172 (GILES-KOMAR JILL [US], et al);
		[Y]US2008081041 (NEMETH JEFFREY [US]);
		[Y]US2004161426 (TRIKHA MOHIT [US], et al);
		[Y] - SHARMA ET AL., "Involvement of Hepcidin in the Anemia of Multiple Myeloma.", CLIN CANCER RES., (2008), vol. 14, no. 11, pages 3262 - 3267, XP008158293 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-07-4153
		[Y] - KAWABATA ET AL., "Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.", HAEMATOLOGICA, (2007), vol. 92, no. 6, pages 857 - 858, XP002467767 DOI: http://dx.doi.org/10.3324/haematol.10794
		[AP] - SCHIPPERUS ET AL., "CNT0328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC)", 51th ASH Annual Meeting and Ecposition, (20091203), XP008158301

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p